Overview

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
Phase:
PHASE2
Details
Lead Sponsor:
AstraZeneca